In re Synthes, Inc. Shareholder Litigation

50 A.3d 1022, 2012 WL 3594293, 2012 Del. Ch. LEXIS 196
CourtCourt of Chancery of Delaware
DecidedAugust 17, 2012
DocketCivil Action No. 6452
StatusPublished
Cited by55 cases

This text of 50 A.3d 1022 (In re Synthes, Inc. Shareholder Litigation) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Synthes, Inc. Shareholder Litigation, 50 A.3d 1022, 2012 WL 3594293, 2012 Del. Ch. LEXIS 196 (Del. Ct. App. 2012).

Opinion

OPINION

STRINE, Chancellor.

I. Introduction

On this motion to dismiss, plaintiff stockholders argue that they have stated a claim for breach of fiduciary duty because a controlling stockholder refused to consider an acquisition offer that would have cashed out all the minority stockholders of the defendant Synthes, Inc., but required the controlling stockholder to remain as an investor in Synthes. Instead, the controlling stockholder worked with the other directors of Synthes and, after affording a consortium of private equity buyers a chance to make an all-cash, all-shares offer, ultimately accepted a bid made by Johnson & Johnson for 65% stock and 35% cash, and consummated a merger on those terms (the “Merger”). The controlling stockholder received the same treatment in the Merger as the other stockholders. In other words, although the controller was allowed by our law to seek a premium for his own controlling position, he did not and instead allowed the minority to share ratably in the control premium paid by J & J. The Synthes board of directors did not accept J & J’s initial bid, but instead engaged in extended negotiations that resulted in J & J raising its bid substantially. The private equity group’s bid for only a part of the company’s equity never reached a price level as high as J & J’s bid and the private equity group never made an offer to buy all of Synthes’ equity.

In this decision, I dismiss the complaint. Contrary to the plaintiffs, I see no basis to conclude that the controlling stockholder had any conflict with the minority that justifies the imposition of the entire fairness standard. The controlling stockholder had more incentive than anyone to maximize the sale price of the company, and Delaware does not require a controlling stockholder to penalize itself and accept less than the minority, in order to afford the minority better terms. Rather, pro rata treatment remains a form of safe harbor under our law.

Furthermore, this case is not governed by Revlon, under the settled authority of our Supreme Court in In re Santa Fe Pacific Corp. Shareholder Litigation.1 And even if it were, the complaint fails to plead facts supporting an inference that Synthes’ board failed to take reasonable steps to maximize the sale price of the company. The complaint in fact illustrates that the board actively solicited logical strategic and private equity buyers over an unhurried time period, and afforded these parties access to due diligence to formulate offers, cites no discrimination among interested buyers, and reveals that the board did not accept J & J’s offer even after it seemed clear no other bidder would top that offer, but instead bargained for more.

In sum, the facts pled do not support an inference that there was any breach of fiduciary duty on the part of the controlling stockholder or members of the board of directors. This is the second amended complaint brought by the plaintiffs, who have already been afforded some written discovery. In these circumstances, allowing the plaintiffs a fourth swing of the bat would not serve the interests of justice, and thus I grant the defendants’ motion to dismiss with prejudice.2

[1025]*1025II. Factual Background3

A. Synthes, Its Board, And Its Controlling Stockholder

Before the Merger, Synthes was a global medical device company incorporated in Delaware with its headquarters in Switzerland, and whose common stock traded on the SIX Swiss Exchange. The company’s certificate of incorporation included a § 102(b)(7) provision eliminating personal director liability for breaches of the duty of care.

Synthes’ board (the “Board”) was composed of ten directors, each of whom is a defendant in this action. The most notable of the directors for purposes of this motion is Swiss billionaire Hansjoerg Wyss, the 76-year-old Chairman of the Board and Synthes’ alleged controlling stockholder. Mr. Wyss founded Synthes in the 1970s and served as its CEO for thirty years until his retirement in 2007. The plaintiffs 4 allege that Wyss controlled a majority of the board by dominating five other members through a mix of alleged close familial and business ties.5 The plaintiffs effectively concede the independence of the remaining four directors. In terms of voting control, Wyss owned 38.5% of the company’s stock, making him the company’s largest stockholder.6 The plaintiffs further allege, however, that Wyss controlled approximately 52% of Synthes’ shares through his control of 13.25% of the company’s shares owned by family members and trusts.7

According to the plaintiffs, Wyss was well past retirement age and getting ready at some point to step down as Chairman of the Board from the company he spent many years of his life building. As part of that plan, he wanted to divest his stock-holdings in Synthes and free up that wealth in order to achieve certain estate planning and tax goals.8 Doing so piecemeal would be problematic, however, because unloading that much stock on the public market in blocs would cause the share price to drop, thus reducing his sale profits.9 So, the plaintiffs contend, in order to achieve his liquidity goals in view of Synthes’ allegedly thin public float, Wyss needed to sell his personal holdings to a single buyer. Wyss was by far the largest stockholder of Synthes (with the next largest non-affiliated stockholder holding only a 6% stake10), and thus was the only stockholder who could not liquidate his entire [1026]*1026Synthes stake on the public markets without affecting the share price.11 The plaintiffs contend that this “unique” liquidity dilemma infected the entire sale process ultimately consummated by the Merger.12

B. The Board Embarks On The Merger Process

[I] The idea to find a potential buyer for Synthes arose in April 2010 as part of the Board’s ongoing review of the company’s strategic initiatives. The complaint alleges that Wyss “supported” the decision to explore a sale transaction, although the complaint does not allege whose idea it was in the first instance.13 In that regard, it is notable that the complaint itself says that it is “summarizing]” the Amended Proxy Statement (the “Proxy Statement”), and refers to the Proxy Statement as “attesting] to [Wyss’] dominance of the sales process,”14 when the Proxy Statement clearly states that the impetus of the transaction came from the Board, not Wyss.15 This pleading approach bears emphasis. The plaintiffs got some written discovery and this is their second amended complaint. But, the complaint relies heavily on the Proxy Statement for its allegations, as it specifically admits,16 and clearly incorporates that document. Having premised their recitation of the facts squarely on that document and incorporated it, the plaintiffs cannot fairly, even at the pleading stage, try to have the court draw inferences in their favor that contradict that document, unless they plead non-conclusory facts contradicting it.17

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gregory B. Maffei v. Dennis Palkon
Supreme Court of Delaware, 2025
In re Dura Medic Consolidation Litigation
Court of Chancery of Delaware, 2025
Manti Holdings, LLC v. The Carlyle Group Inc.
Court of Chancery of Delaware, 2025
Goldstein v. Denner
Court of Chancery of Delaware, 2022
Walter E. Ryan, Jr. v. Buckeye Partners, L.P., et a.
Court of Chancery of Delaware, 2022
In Re: MultiPlan Corp. Stockholders Litigation
Court of Chancery of Delaware, 2022
Cindy Harcum v. John Lovoi
Court of Chancery of Delaware, 2022
John H. Kihm v. David M. Mott
Court of Chancery of Delaware, 2021
Suzanne Flannery v. Genomic Health Inc.
Court of Chancery of Delaware, 2021
In re Appraisal of Regal Entertainment Group
Court of Chancery of Delaware, 2021
RCS Creditor Trust v. Nicholas S. Schorsch
Court of Chancery of Delaware, 2021
In Re: Mindbody, Inc. Stockholders Litigation
Court of Chancery of Delaware, 2020
In re Appraisal of Stillwater Mining Company
Court of Chancery of Delaware, 2019

Cite This Page — Counsel Stack

Bluebook (online)
50 A.3d 1022, 2012 WL 3594293, 2012 Del. Ch. LEXIS 196, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-synthes-inc-shareholder-litigation-delch-2012.